Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
Niels Willem Boone, Roelof Wouter Frederik van LeeuwenMaastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The NetherlandsRecently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, rec...
Saved in:
Main Authors: | Boone NW, van Leeuwen RWF |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/43edcb1ca8cf4cafa08fd527b225072a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
by: Luis Arias, et al.
Published: (2010) -
Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab
by: Sukhpal Singh Sandhu, et al.
Published: (2010) -
An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood
by: Shuai Sun, et al.
Published: (2021) -
Case–control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood
by: Hellen Hiza, et al.
Published: (2021) -
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
by: Mitsunori Ishiguro, et al.
Published: (2010)